Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATTAIN-2: Orforglipron in Adults With Obesity or Overweight and Type 2 Diabetes
NCT05872620Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jun 2023
- Primary completion
- Aug 2025
- Modality
- Small Molecules
- Countries
- 11
01
Overview
Phase 3, randomised, double-blind trial of orforglipron in obesity and type 2 diabetes mellitus (T2DM) (4 arms), sponsored by Eli Lilly and Company. Primary endpoint: Percent Change From Baseline in Body Weight at 72 weeks. Started Jun 2023; status: completed.
02
Drugs
orforglipron
03
Conditions
obesitytype 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT05872620.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05872620.